Glaucoma Eye Drops Market Analysis | Coherent Market Insights

1
Coherent Market InsightS

• Market Research and Business Consulting
  Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
Glaucoma Eye Drops Market Analysis (2020-2027)

• Glaucoma refers to the group of conditions
  characterized by optic nerve damage, visual field
  loss, and secondary to retinal ganglion cell
  damage, which can lead to death.
• According to the International Agency for the
  Prevention of Blindness 2017, glaucoma is the
  second leading cause of blindness and leading
  cause of irreversible blindness, worldwide. The
  most common types of glaucoma are primary open
  angle glaucoma (POAG) and primary angle closure
  glaucoma (PACG).

3
s

• The significant risk of developing glaucoma
  increases with age, increased intraocular
  pressure, positive family history for glaucoma,
  and ethnicity.
• For instance, according to the American Academy
  of Ophthalmologys 2016 report, the global
  prevalence of glaucoma is estimated to rise to 76
  million in 2020 and 111.8 million in 2040.

4
COVID-19 IMPACT ANALYSIS

• The coronavirus pandemic has drastically altered
  the lives of patients of glaucoma everywhere, and
  everyone is grappling with changes to health,
  daily routines, and management of glaucoma during
  the coronavirus pandemic. According to the World
  Health Organization Coronavirus Disease
  (COVID-19) Dashboard (WHO), the manifestation of
  the coronavirus has resulted in more than 7
  million infected individuals worldwide as of June
  2020.
• According to the Bright Focus Foundations data
  of April 15, 2020, glaucoma is more prevalent in
  the African American population. African
  Americans also experience higher prevalence of
  diabetes and hypertension which makes them
  especially vulnerable to COVID-19 infection.

5
s

• The WHO has encouraged ophthalmic drug
  manufacturing companies to take safety and
  responsible measures in order to reduce the
  spread of coronavirus. For instance, limiting the
  number of people in one area at a time, modifying
  workstation arrangements, and minimizing the
  cross flow of people between shifts to reduce
  potential exposure, along with enhanced cleaning
  and sanitization of facilities.
• The American Academy of Ophthalmology has
  prudently issued a statement to cease all
  non-urgent care in the office and all elective
  surgeries in the operating room to preserve
  much-needed resources.
• Healthcare providers, including ophthalmologists,
  may be called upon and deployed to the frontline
  to care for patients infected with COVID-19.
  Clinics are taking steps to ensure utmost safety
  for the patients.
• The Glaucoma Eye Drops Market is estimated to be
  valued at US 1,360.1 million in 2020 and is
  expected to exhibit a CAGR of 7.0 during the
  forecast period (2020-2027).

6
Figure 1. Global Glaucoma Eye Drops Market Share
() Analysis, By Drug Type, 2020
7
The increasing number of product launches and
approvals are expected to drive the growth of
glaucoma eye drops market.

• Several novel glaucoma eye drops have been
  approved by regulatory bodies in different
  countries and major players in the market have
  launched various novel and innovative glaucoma
  eye drops. Rapid approvals and launches of novel
  products in the market are expected to be a major
  driver for growth of the glaucoma eye drops
  market.
• For instance, in March 2019, the U.S. Food and
  Drug Administration (FDA) approved Aerie
  Pharmaceuticals' Rocklatan (netarsudil and
  latanoprost ophthalmic solution) for treatment of
  open-angle glaucoma or ocular hypertension.

8

• Rocklatan is a once-daily eye drop that is a
  fixed-dose combination of latanoprost, the most
  widely-prescribed prostaglandin analog (PGA), and
  netarsudil, the active ingredient in Rhopressa
  (netarsudil ophthalmic solution) 0.02. It is a
  first-in-class Rho kinase (ROCK) inhibitor
  specifically designed to target the trabecular
  meshwork.
• The glaucoma eye drops market is expected to
  witness high growth and generate high revenue
  owing to product launches for the treatment of
  glaucoma during the forecast period. For
  instance, in June 16 2020, Senju Pharmaceutical
  Co., Ltd. and Otsuka Pharmaceutical Co., Ltd.
  announced that a new combination ophthalmic
  solution for the treatment of glaucoma and ocular
  hypertension, AILAMIDE Combination Ophthalmic
  Suspension (generic name brimonidine
  tartrate/brinzolamid), has been launched in
  Japan. Senju Pharmaceutical Co., Ltd. (marketing
  authorization holder) and Otsuka Pharmaceutical
  Co., Ltd. (collaborator) will conduct activities
  related to the provision of drug information for
  this drug.

9
Glaucoma Eye Drops Market - Restraints

• However, glaucoma is a disease that cannot be
  cured, but it can be controlled. Eye drops,
  pills, laser procedures, and surgical operations
  are used to prevent or slow further damage from
  occurring.
• Glaucoma is an irreversible disease, and the
  extensive RD activities make the drug very
  expensive which is expected to hamper the
  glaucoma eye drops market growth during the
  forecast period.
• For instance, according to data published by the
  National Center for Biotechnology Information,
  yearly cost of prostaglandin analogs ranged from
  US 427.69 for Travatan (Alcon) to US 577.62 for
  Lumigan (Allergan).

10
s

• Alphagan P 0.15 had yearly calculated costs of
  US 559.08 for twice daily dosing per eye. Cosopt
  (Merck Co.) costs as high as US 697.42 to US
  873.98.

11
(No Transcript)
12
Glaucoma Eye Drops Market Regional Analysis

• North America accounted for the largest share in
  the glaucoma eye drops market in 2019, owing to
  the increasing number of product launches and
  approvals of glaucoma eye drops by regulatory
  bodies.
• For instance, in November 2017, Bausch Lomb, a
  subsidiary of Valeant Pharmaceuticals
  International, Inc., and Nicox S.A., received
  U.S. Food and Drug Administrations approval of
  the New Drug Disease Indication (NDA) for
  VYZULTA, indicated for the treatment of
  open-angle glaucoma. Furthermore, Asia Pacific is
  expected to observe the fastest growth during the
  forecast period

13

• . Market players are focusing on various
  inorganic strategies such as mergers and
  agreements. For instance, in December 2018, Nicox
  SA entered an exclusive license agreement with
  Ocumension Therapeutics for the development and
  commercialization of NCX 470, an ophthalmic
  solution, in China, Hong Kong, Macau, and Taiwan.

14
Figure 2. Global Glaucoma Eye Drops Market Value
(US Mn) Y-o-Y Growth (), 2017-2027
15
Glaucoma Eye Drops Market - Competitive Landscape

• Key players operating in the glaucoma eye drops
  market are Merck Co., Inc., Allergan Plc.
  Novartis AG. Teva Pharmaceutical Industry,
  Pfizer, Inc., Bausch Lomb Inc., Inotek
  Pharmaceutical, Jadran-galenski laboratorij d.d.,
  Aerie Pharmaceutical, and Mylan N.V.

16

• Request sample copy here
• Request PDF brochure here
• Request Customization here
• Talk to Analyst
• Buy Now
• Reference
• https//www.coherentmarketinsights.com/market-insi
  ght/glaucoma-eye-drops-market-3984

17
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

18
Contact Us   

• Mr. Shah
• Coherent Market Insights Pvt. Ltd.
• Address 1001 4th ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

19
Thank You!

• Kindly follow CMI Social Media Profiles for the
  latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/